Netzel B, Rodt H, Thiel E, Haas R J, Thierfelder S
Klin Padiatr. 1979 Mar;191(2):175-81.
Acute lymphatic leukaemia (ALL) in infants is a very heterogeneous disease from the immunological point of view. Phaenotyping of leukaemic cells in 138 patients via different immunmarkers has so far allowed subdivision into 6 subgroups. Clinical risk factors and correlations with the immunologically defined subgroups, as well as their significance for prognosis, are demonstrated with the help of 61 examined ALL patients. 90-95% of all acute lymphatic leukaemias can presently be identified via heterologous antisera. After corresponding absorption, these antisera show high cytotoxicity against ALL cells without displaying any aggressivity towards normal haemopoetic stem cells. The authors make therapeutic use of anti-T cell and anti-common ALL (cALL) globulin in autologous bone marrow transplantation. This method involves withdrawal of bone marrow from patients with ALL in complete remission, the marrow being then fractionated, treated with antiserum to destroy residual leukaemic cells, and then cryopreserved. The leukaemia-free bone marrow will thus be available for transplantation in relapse.
从免疫学角度来看，婴儿急性淋巴细胞白血病（ALL）是一种非常异质性的疾病。迄今为止，通过不同免疫标志物对138例患者的白血病细胞进行表型分析，可将其细分为6个亚组。借助61例接受检查的ALL患者，展示了临床危险因素以及与免疫定义亚组的相关性，及其对预后的意义。目前，所有急性淋巴细胞白血病的90% - 95%可通过异种抗血清进行识别。经过相应吸收后，这些抗血清对ALL细胞显示出高细胞毒性，而对正常造血干细胞无任何侵袭性。作者在自体骨髓移植中治疗性地使用抗T细胞和抗普通ALL（cALL）球蛋白。该方法包括从完全缓解的ALL患者中提取骨髓，然后对骨髓进行分离，用抗血清处理以破坏残留的白血病细胞，随后进行冷冻保存。这样，无白血病的骨髓可用于复发时的移植。
